$Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience$

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-naïve (TN) older patients (≥65 years of age) and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We now report on long-term effi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2018-04, Vol.131 (17), p.1910-1919
Hauptverfasser:	O'Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - analogs & derivatives Adult Aged Aged, 80 and over Clinical Trials and Observations Disease-Free Survival Female Follow-Up Studies Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - metabolism Leukemia, Lymphocytic, Chronic, B-Cell - mortality Male Middle Aged Piperidines Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrimidines - administration & dosage Pyrimidines - adverse effects Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!